Background-The diabetic heart exhibits increased left ventricular (LV) mass and reduced ventricular function. However, this relationship has not been studied in patients with aortic stenosis (AS), a disease process that causes LV hypertrophy and dysfunction through a distinct mechanism of pressure overload. The aim of this study was to determine how diabetes mellitus (DM) affects LV remodeling and function in patients with severe AS. Methods and Results-Echocardiography was performed on 114 patients with severe AS (mean aortic valve area [AVA], 0.6 cm 2 ) and included measures of LV remodeling and function. Multivariable linear regression models investigated the independent effect of DM on these aspects of LV structure and function. Compared to patients without diabetes (nϭ60), those with diabetes (nϭ54) had increased LV mass and LV end-systolic and end-diastolic dimensions, and decreased LV ejection fraction (EF) and longitudinal systolic strain (all PϽ0.01). In multivariable analyses adjusting for age, sex, systolic blood pressure, AVA, body surface area, and coronary disease, DM was an independent predictor of increased LV mass (␤ϭ26 g, Pϭ0.01), LV end-systolic dimension (␤ϭ0.5 cm, Pϭ0.008), and LV end-diastolic dimension (␤ϭ0.3 cm, Pϭ0.025). After also adjusting for LV mass, DM was associated with reduced longitudinal systolic strain (␤ϭ1.9%, Pϭ0.023) and a trend toward reduced EF (␤ϭϪ5%, Pϭ0.09). Among patients with diabetes, insulin use (as a marker of disease severity) was associated with larger LV end-systolic dimension and worse LV function. LV mass was a strong predictor of reduced EF and systolic strain (both PϽ0.001). Conclusions-DM has an additive adverse effect on hypertrophic remodeling (increased LV mass and larger cavity dimensions) and is associated with reduced systolic function in patients with AS beyond known factors of pressure overload. (Circ Heart Fail. 2011;4:286-292.)
D iabetes mellitus (DM) increases the risk of developing and exacerbates the complications of all forms of cardiovascular disease. 1, 2 DM can directly affect the myocardium, leading to increased left ventricular (LV) hypertrophy, altered LV remodeling, and reduced LV function. 3 In the presence of hypertension or ischemia, DM exacerbates adverse LV remodeling and dysfunction, which results in worse heart failure symptoms and increased mortality. 4 -6 As the prevalence of DM reaches epidemic levels, the relationship between DM and LV remodeling and heart failure becomes increasingly important to understand.
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In patients with aortic stenosis (AS), LV hypertrophy is associated with reduced systolic and diastolic function, 7 increased operative mortality, 8 and worse long-term outcomes. 9 Prior studies of LV hypertrophic remodeling in patients with AS have predominantly investigated the impact of pressure overload (aortic valve area [AVA], valve gradients, blood pressure, arterial stiffness) and sex. 10 -12 Despite evidence that the diabetic heart exhibits increased LV mass and reduced ventricular function, most studies have focused on the impact of DM on the development and progression of valve calcification and stenosis. 13, 14 The role of DM in adverse LV remodeling has not been explored in patients with AS.
The importance of investigating the influence of DM on LV remodeling in patients with AS is supported by recent evidence that patients with AS and insulin resistance (in the form of the metabolic syndrome) have an increased LV mass index and reduced LV function. 15 In addition, preclinical data using a mouse model of diet-induced obesity demonstrated that animals fed a high-fat diet, which caused insulin resistance and hyperglycemia, developed more pronounced LV hypertrophy and dysfunction after aortic banding than mice fed a standard diet. 16 Given the known effects of DM on the LV in patients without AS and emerging data about the influence of metabolic disturbances on LV remodeling, we hypothesized that DM adversely affects LV remodeling and LV function in patients with AS beyond traditional factors of pressure overload.
Methods

Patient Population
Between February 2008 and June 2010, 114 consecutive study participants were recruited from patients referred for high-risk aortic valve replacement and scheduled for a clinically indicated echocardiogram to evaluate severe symptomatic AS at Barnes Jewish Hospital in St Louis, Missouri. Patients had to be aged Ն18 years and have an AVA index Ͻ0.6 cm 2 /m 2 . Patients with irregular rhythms or echocardiographic windows that precluded accurate 2D measurements were excluded. Institutional Review Board approval was obtained, and all patients signed a written informed consent.
Clinical Data
Clinical variables were obtained through patient interview and chart abstraction. The diagnosis of DM was determined from the medical record and confirmed by patient interview. Prior myocardial infarction was defined as pathological Q waves on ECG, history of elevated troponin thought to be related to an acute coronary syndrome, history of myocardial infarction as stated in the medical record, or evidence of infarct on nuclear imaging. Coronary artery disease was defined as prior myocardial infarction; prior percutaneous or surgical revascularization; or any stenosis in the left anterior descending, left circumflex, right coronary, or left main arteries Ն50%. The diagnosis of hypertension was made on the basis of medical history, use of antihypertensive medication(s), or blood pressure Ͼ140/90 mm Hg. Blood pressure and New York Heart Association (NYHA) functional class were determined at the time of echocardiography.
Echocardiographic Data
Parasternal and apical views were used to acquire standard 2D and Doppler images on a GE Vivid 7 ultrasound system using a multifrequency transducer with tissue Doppler echocardiography capability. Echocardiograms were analyzed by 3 cardiologists blinded to patient diabetic status. The severity of AS was determined by measuring mean and peak gradients across the valve using the modified Bernoulli equation and by calculating AVA using the continuity equation. AVA was indexed to body surface area (BSA). Systemic arterial compliance and valvuloarterial impedance were calculated as previously described. 12 The severity of mitral regurgitation was determined by the integrative approach recommended by the American Society of Echocardiography. 17
LV Remodeling and Function
The LV minor axis internal dimensions were measured at end systole (LV end-systolic dimension [LVESD]) and end diastole (LV enddiastolic dimension [LVEDD]) in the parasternal long-axis view. Posterior wall thickness (PWT) was measured at end diastole in the same view. LV mass was calculated by the area-length method and indexed to BSA. Relative wall thickness (RWT) was calculated as follows: RWTϭ(2ϫPWT)/LVEDD. Stroke volume was calculated (LVOT radius) 2 ϫLVOT velocity time integral, where LVOT indicates LV outflow tract, and was indexed to BSA. LV ejection fraction (LVEF) was measured using the biplane Simpson method. The septal and lateral early diastolic mitral annular velocity (eЈ) was acquired using tissue Doppler echocardiographic imaging from the apical 4-chamber view; the average was reported. E/eЈ represents the peak E-wave velocity from the pulse Doppler echocardiographic measurement of mitral valve inflow divided by the averaged eЈ. All measurements reflect an average of several values and were made in accordance with the recommendations of the American Society of Echocardiography. 18
Longitudinal Systolic Strain and Strain Rate
Standard 2D apical 2-, 3-, and 4-chamber views obtained at a frame rate of 60 to 80 frames per second were analyzed with GE EchoPac version 7.2 and 108.1.5 (GE Vingmed Ultrasound AS; Horten, Norway) analysis software to measure strain and strain rate using the speckle tracking method. In each apical view, the LV endocardium was traced at end systole, and the region of interest width was adjusted to fit the myocardial wall thickness. The software automatically tracked the motion through the rest of the cardiac cycle. The beginning of systole was established as the end of the QRS complex by ECG analysis, whereas the timing of end systole was determined using continuous-wave Doppler echocardiography through the aortic valve. Adequate tracking of the ventricular myocardium was verified in real time, and inadequately tracked segments were excluded from analysis. LV peak longitudinal systolic strain and peak systolic strain rate were measured in all 18 segments of the myocardium. 19 Strain and strain rate were averaged across the 6 segments within the basal, mid, and apical regions of the LV. The values for the 3 regions were then averaged, yielding a global average for the entire myocardium. If Ͼ1 segment per region had inadequate tracking, the patient was excluded from strain analysis.
Statistical Analysis
Demographic, clinical, and echocardiographic characteristics were compared between patients with and without diabetes using 2 test for categorical variables and t test for continuous variables. NYHA functional class was compared between groups using the Cochran-Armitage trend test.
To assess the effect of DM on LV remodeling, multivariable linear regression models were constructed to evaluate the impact of DM on LV mass (primary structural variable), LVESD, LVEDD, and RWT. Balancing increased discrimination with overfitting, covariates were selected a priori on the basis of clinical judgment and included DM, age, sex, BSA, systolic blood pressure, AVA, and coronary disease. BSA was selected as a covariate given its relationship with indexing LV mass and AVA. However, given the strong univariable and known physiological association between body mass index (BMI) and LV mass, we performed sensitivity analyses that included BMI as a covariate instead of BSA (both were not included given collinearity).
To assess the effect of DM on LV function, multivariable linear regression models were constructed to evaluate the impact of DM on longitudinal systolic strain (primary functional variable), LVEF, average eЈ, and longitudinal strain rate. Covariates in functional models included the same variables as the structural models with the addition of LV mass, the primary structural variable.
As an exploratory analysis, an ordinal logistic regression model was constructed to evaluate the effect of DM on heart failure symptoms. Because of small numbers, patients with NYHA Class I and II symptoms were combined into a single group. Covariates in the model included the same variables as the functional models with the addition of systolic strain as the primary functional variable. Ordinal logistic regression, which allows the outcome variable to have Ͼ2 categories, assumes a proportional odds ratio for each predictor for each combination of higher-risk categories versus lower-risk categories (eg, NYHA Class IV versus NYHA Class I-III and NYHA Class III-IV versus NYHA Class I-II). The validity of the proportional odds assumption, assessed with the Score test, 20 was met for the model.
Because of issues with multiple comparisons, a primary structural outcome (LV mass) and primary functional outcome (LV systolic strain) were selected, and a Bonferroni correction was used. Accordingly, a PϽ0.025 was considered to be statistically significant for these analyses. All other tests of statistical significance were evaluated at a 2-sided significance level of 0.05 with 95% CIs. All statistical analyses were performed using SAS for Windows version 9.2 (SAS Institute Inc; Cary, NC).
Results
The primary goal of our study was to determine the association of DM with LV remodeling and LV function in patients with severe AS.
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Patient Population
Among 114 patients with severe symptomatic AS included in this study, the average age was 82 years, 54 (47%) were women, the mean AVA was 0.6 cm 2 , the mean LVEF was 50%, and 54 (47%) had diabetes. The baseline demographic and clinical characteristics of patients with and without DM are shown in Table 1 . The patients with diabetes were younger, more often men, had larger BMIs, and had higher B-type natriuretic peptide levels than those without diabetes. The prevalence of coronary disease, prior infarct, and hypertension were similar in both patient groups as were the levels of blood pressure, renal function, and cholesterol. As expected, the patients with diabetes were more frequently prescribed angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers. The severity of AS by valve area and gradients was similar between the study groups ( Table 2) . (Table 3 ). After controlling for age, sex, BSA, systolic blood pressure, AVA, and coronary disease, the LVs of the patients with diabetes were, on average, 26 g heavier (95% CI, 6.6 to 45.0; Pϭ0.01), 0.5 cm larger in diameter at end systole (95% CI, 0.15 to 0.93; Pϭ0.008), and 0.3 cm larger in diameter at end diastole (95% CI, 0.04 to 0.60; Pϭ0.025) than the LVs of the patients without diabetes. DM was not associated with RWT after multivariable adjustment (Pϭ0.51). When these analyses were performed substituting BMI for BSA (to ensure that our results were not confounded by the effect of obesity on LV remodeling) the relationship between DM and adverse LV remodeling was slightly stronger. The impact of insulin use (as a marker of disease severity) on LV remodeling was assessed in the patients with diabetes. In univariable analysis, patients taking insulin versus those not taking insulin trended toward larger LV mass (283 versus 259 g, Pϭ0.09), although this association was not significant after multivariable adjustment (Pϭ0.47). Patients with diabetes taking insulin versus no insulin had larger LVESD (4.1 versus 3.5 cm, Pϭ0.02); after adjusting for factors known to affect LV remodeling, insulin use was associated with an increased LVESD (␤ϭ0.6 cm, Pϭ0.02). There was no association in either univariable or multivariable analyses of insulin use with LVEDD or RWT.
LV Remodeling
LV Function
Patients with diabetes, compared to those without diabetes, had evidence of decreased systolic function, with worse longitudinal systolic strain (Ϫ12% versus Ϫ15%, Pϭ0.001), LVEF (45% versus 55%, Pϭ0.006), and longitudinal systolic strain rate (Ϫ0.8 versus Ϫ0.9 s Ϫ1 , Pϭ0.024) ( Table 2) . Diastolic function as measured by eЈ was similar between the groups, but there was a trend toward an increased filling pressure in those with diabetes as measured by E/eЈ (DM versus non-DM, 28 versus 23; Pϭ0.079). Measures of global LV load and vascular compliance were similar between the groups, as was the severity of mitral regurgitation.
To evaluate the independent effect of DM on LV function beyond factors of pressure overload and LV remodeling, multi-variable analyses were performed to control for variables known to influence LV function ( Table 4 ). After adjusting for the same covariates as previously described in addition to LV mass, longitudinal systolic strain was, on average, 1.9% worse (95% CI, 0.3 to 3.6; Pϭ0.023), and LVEF was 5.3% worse in patients with diabetes than in those without diabetes, although the association between DM and LVEF did not reach statistical significance (95% CI, Ϫ11.4 to 0.8; Pϭ0.09). Longitudinal systolic strain rate (Pϭ0.11) and eЈ (Pϭ0.75) were not associated with DM after multivariable adjustment. LV mass was strongly associated with all measures of reduced systolic and diastolic function (PՅ0.01 for all analyses) ( Table 4 ). Again, when BMI was substituted for BSA in the multivariable analyses of LV function, the relationship between DM and reduced LV function was slightly stronger.
The impact of insulin use on LV function also was assessed among patients with diabetes. Those taking insulin versus no insulin had worse systolic strain (Ϫ10.0% versus Ϫ13.5%, Pϭ0.01), lower LVEF (40.0% versus 49.7%, Pϭ0.04), and worse strain rate (Ϫ0.74 versus Ϫ0.89 s Ϫ1 , Pϭ0.03). After multivariable adjustment, insulin use was associated with worse systolic strain (␤ϭ2.4%, Pϭ0.05), lower LVEF (␤ϭϪ10.9%, Pϭ0.01), and a trend toward worse strain rate (Pϭ0.06). There was no association of insulin use with average eЈ.
NYHA Class
Given the influence of DM on LV structure and function, an exploratory analysis was performed to determine the independent effect of DM on functional capacity in patients with Abbreviations as in Table 2 .
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severe AS. After controlling for the same covariates as previously described in addition to LV systolic strain, there was a trend toward patients with diabetes having a worse NYHA class than those without diabetes (odds ratio, 2.5; 95% CI, 0.97 to 6.67; Pϭ0.059) ( Table 5 ).
Discussion
In patients with severe AS, DM has an additive adverse effect on LV remodeling and LV function, with increased hypertrophic remodeling (increased LV mass and larger cavity dimensions) and reduced LV systolic function. These effects remained significant even after controlling for factors of pressure overload and sex that are known to influence LV remodeling and function in patients with AS. Furthermore, we found that increased LV mass was a strong predictor of decreased LV systolic and diastolic function, which is consistent with multiple prior studies that demonstrated that pronounced LV hypertrophic remodeling in patients with severe AS is maladaptive. [7] [8] [9] 21 Because DM had a deleterious effect on LV function independent of increased LV mass and body size, the present study suggests that DM adversely affects LV function through a combination of increased LV mass and additional undefined deleterious effects on the myocardium itself. Finally, we found that patients with diabetes also trend toward having decreased functional capacity that appears to be independent of an effect of LV structure and function. To our knowledge, this report is the first to investigate the impact of DM on LV structure and function in patients with AS.
Diabetes and the LV: Comparison With Prior Studies
Prior studies in patients without AS have demonstrated that DM is associated with increased LV mass, higher absolute and RWT, and decreased LV systolic and diastolic function. 3, 22 Patients with diabetes also exhibit relatively greater increases in LV hypertrophy and dysfunction in the face of systemic hypertension and ischemia/infarction than those without diabetes; these changes are associated with worse heart failure symptoms and outcomes in patients with diabetes. 4 -6 The present study results are consistent with these prior observations and extend these findings to patients with both DM and AS, a population that previously has not been well characterized.
The present study also expands on the recent report by Page et al 15 that evaluated the effects of the metabolic syndrome on LV structure and function in patients with asymptomatic, mild to moderate AS. Both investigations demonstrated that metabolic abnormalities are associated with increased LV mass index and reduced LV function in patients with AS. However, Page et al noted that the metabolic syndrome was associated with a different manner of remodeling in patients with less severe AS: increased absolute and RWT but similar chamber dimensions. The differences in LV remodeling seen by Page et al may be due to the type and severity of metabolic disturbance (DM versus the metabolic syndrome), the severity of AS (severe symptomatic AS versus mild to moderate asymptomatic AS), or other factors. Considering the present results in combination with the study by Page et al, however, raises the possibility that in the face of a metabolic disturbance (DM, the metabolic syndrome, or both), the LV initially responds to the pressure overload with an increase in LV mass and RWT, but over time as the AS progresses, the LV of patients with diabetes is likely to decompensate more rapidly, with increased LV dilation and reduced LV function. Further longitudinal studies are needed to characterize the influence of DM and the metabolic syndrome (alone and together) on LV remodeling and function as AS progresses.
Potential Mechanisms for Adverse Remodeling and Decreased Function Among Patients With Diabetes and AS
Although this study was not designed to determine the molecular mechanisms by which DM affects the myocardium, there are several potential mechanistic explanations for our findings. Type 2 DM is characterized by a milieu of hyperinsulinemia, insulin resistance, hyperglycemia, and increased nonesterified fatty acids, which contribute to lipotoxicity, oxidative stress, advanced glycation end products, and altered calcium handling and substrate metabolism. [23] [24] [25] [26] In the myocardium, these changes promote fibrosis, apoptosis, and myocyte hypertrophy, which have structural and functional consequences. 24 Pressure overload also induces changes in molecular signaling pathways that lead to similar deleterious structural and functional changes. 27 Whether and how these 2 stimuli (DM and AS) interact to influence signaling pathways and myocardial structure and function is not known; this area is ripe for further evaluation, particularly given the findings of the present study.
Clinical Implications
Given the well-documented adverse effects of LV hypertrophy in patients with AS, the present study findings of the additive effect of DM on LV remodeling and LV function have important clinical implications. Previous reports have focused on the impact of the stenotic valve on this remodeling process, which currently is only modifiable through surgical intervention with valve replacement. Our study has identified a risk factor for accentuated LV hypertrophy in patients with AS that may be a therapeutic target. Given the adverse impact of DM in patients with AS, future studies should evaluate whether better DM control (perhaps with specific medications) prevents adverse remodeling and its attendant consequences.
Additionally, because adverse remodeling and reduced LV function are known to affect outcomes, our findings that patients with diabetes are more likely to have increased LV mass and LV dilation with decreased systolic function may influence decisions on the timing and type of valve replacement. In patients with severe AS, DM has been associated with higher mortality. 28 At our own institution, an analysis of 1080 patients with AS over the past decade showed that DM was an independent predictor of decreased survival after aortic valve replacement (R.J. Damiano, Jr, MD, unpublished data, April 2010). It is tempting to speculate that earlier surgical intervention in patients with diabetes and severe AS (perhaps while they are asymptomatic) may reduce this disparity in outcomes; however, this would require prospective evaluation in a lower-risk group of subjects. Furthermore, there may be implications for the type of procedure chosen for valve implantation (open surgery versus transcatheter) because DM may influence how the LV responds to either cardioplegia or rapid ventricular pacing, particularly in patients with underlying LV dysfunction.
DM also may affect the post-valve replacement clinical course. After aortic valve replacement, regression of LV hypertrophy is associated with greater improvement in LV contractility. 29 Because patients with diabetes and hypertension exhibit less regression of LV hypertrophy than those without diabetes when treated with antihypertensive medications, 30 patients with diabetes also may experience less regression of LV hypertrophy or less improvement of LV function after valve replacement, which would be expected to affect symptomatic recovery. All of these questions require further exploration, with answers that will affect our care of patients with diabetes and AS.
Limitations
The present study should be interpreted in the context of the following limitations. This study is a single-center experience at a tertiary-care facility, which could cause referral or other biases and limit the generalizability of the findings. Second, it is a cross-sectional analysis of patients with severe AS, which limits our ability to know how DM affects the LV response to AS over time as the AS worsens. Future longitudinal studies will be needed to address this question and clarify whether DM has an additive or synergistic effect beyond AS in the LV remodeling process. Third, we did not have data on fasting blood glucose or waist circumference, which prevented us from classifying subjects according to the presence or absence of the metabolic syndrome. Moreover, beyond the need for insulin, we were not able to characterize the severity of DM in terms of length of time with the disease or associated microvascular complications. We were able to obtain hemoglobin A1c data on 65% of the patients with diabetes, but this only reflects 3 months of DM control and does not reflect the long-term exposure of the LV to the metabolic effects of DM. Of note, the mean hemoglobin A1c level in our study was 7.1, suggesting that even in this relatively well-controlled diabetic population (at least at the time of their echocardiograms), the differences in LV remodeling and function were still evident. To extend our initial observation of this relationship, it will be important to obtain data on the severity of DM as well as insulin, glucose, and nonesterified fatty acid levels for future studies seeking to clarify and characterize the relationship between DM and LV remodeling in patients with AS. Finally, given the observational nature of the study, there is the potential for unmeasured confounding. Nevertheless, the findings are consistent with the existing literature on DM and LV remodeling.
Conclusions
To our knowledge, this study is the first to show that DM is associated with increased LV hypertrophy, increased chamber dimensions, and reduced systolic function in patients with severe AS, even after controlling for known factors of pressure overload, body size, and other potential confounders. These data extend previous observations about the deleterious influence of DM on LV remodeling and function to a population of patients with AS, a disease process that results in LV hypertrophy and dysfunction through pressure overload. Our observations should stimulate further studies that explore underlying mechanisms, implications for clinical management, and opportunities for pharmacological intervention. A better understanding of how DM influences the LV in patients with AS will be critical for improving management of these high-risk patients.
